Could a common drug curb polyps in teens with rare genetic condition?

NCT ID NCT06308445

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests two low doses of rapamycin, a drug usually used to prevent organ rejection, in 25 teenagers (ages 12-17) with familial adenomatous polyposis (FAP), a genetic condition that causes many colon polyps and raises cancer risk. The main goal is to see if the drug is safe and tolerable. Researchers will also check if it reduces the number or size of polyps. The study is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Rapamycin
What this could lead to
If successful, this could point toward a way to slow or reduce polyp growth in teens with FAP, potentially delaying or avoiding surgery.
What could go wrong
This is a small, early safety study (Phase 2) with only 25 participants. Rapamycin has known side effects, and it is not yet proven to work for FAP. The results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FAMILIAL ADENOMATOUS POLYPOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenomatous Polyposis Coli classic familial adenomatous polyposis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • APHP Hôpital Robert Debré

    Paris, 75019, France

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • CHU Bordeaux Hôpital Pellegrin

    Bordeaux, 33076, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • CHU Montpellier Hôpital Arnaud de Villeneuve

    Montpellier, 34295, France

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • CHU Toulouse Hôpital des Enfants

    Toulouse, 31300, France

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.